kicked off on Tuesday, with Fulcrum Therapeutics Inc (NASDAQ: FULC) stock price down -0.84% from the previous day of trading, before settling in for the closing price of $3.57. FULC’s price has ranged from $2.87 to $13.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -1.10% over the last five years. Meanwhile, its annual earnings per share averaged 82.53%. With a float of $52.73 million, this company’s outstanding shares have now reached $61.92 million.
The firm has a total of 76 workers. Let’s measure their productivity. In terms of profitability, gross margin is 97.69%, operating margin of -40.15%, and the pretax margin is -24.79%.
Fulcrum Therapeutics Inc (FULC) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Fulcrum Therapeutics Inc is 15.49%, while institutional ownership is 82.06%. The most recent insider transaction that took place on May 07 ’24, was worth 1,831. In this transaction Principal Accounting Officer of this company sold 236 shares at a rate of $7.76, taking the stock ownership to the 11,571 shares. Before that another transaction happened on Mar 08 ’24, when Company’s Vice President, Finance sold 4,884 for $11.72, making the entire transaction worth $57,219. This insider now owns 11,807 shares in total.
Fulcrum Therapeutics Inc (FULC) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 82.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.40% during the next five years compared to 1.09% growth over the previous five years of trading.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Trading Performance Indicators
Here are Fulcrum Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 22.07. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.22 in one year’s time.
Technical Analysis of Fulcrum Therapeutics Inc (FULC)
Analysing the last 5-days average volume posted by the [Fulcrum Therapeutics Inc, FULC], we can find that recorded value of 0.77 million was lower than the volume posted last year of 1.03 million. As of the previous 9 days, the stock’s Stochastic %D was 24.85%. Additionally, its Average True Range was 0.50.
During the past 100 days, Fulcrum Therapeutics Inc’s (FULC) raw stochastic average was set at 9.29%, which indicates a significant decrease from 26.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 95.25% in the past 14 days, which was lower than the 168.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.86, while its 200-day Moving Average is $7.79. Now, the first resistance to watch is $3.61. This is followed by the second major resistance level at $3.68. The third major resistance level sits at $3.73. If the price goes on to break the first support level at $3.49, it is likely to go to the next support level at $3.44. Should the price break the second support level, the third support level stands at $3.37.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Key Stats
With a market capitalization of 220.90 million, the company has a total of 62,154K Shares Outstanding. Currently, annual sales are 2,810 K while annual income is -97,340 K. The company’s previous quarter sales were 80,000 K while its latest quarter income was 55,410 K.
